Histogenics announces publication of data from NeoCart trials
Histogenics announced the online publication in the January 2017 issue of the American Journal of Sports Medicine of a peer-reviewed publication entitled Magnetic Resonance Imaging Characterization and Clinical Outcomes After NeoCart Surgical Therapy as a Primary Reparative Treatment for Knee Cartilage Injuries. The lead investigator is Dr. Dennis Crawford MD, PhD with support from other investigators including Devon E. Anderson, PhD, Riley J. Williams III, MD, Thomas M. DeBerardino, MD, Dean C. Taylor, MD, C. Benjamin Ma, MD, and Marie S. Kane, MS. The publication analyzes magnetic resonance imaging (MRI) data through 60 months follow up from the Phase 1 and 2 clinical trials of NeoCart for the repair of articular cartilage injuries in the knee. "We are very pleased with the results of the clinical trials conducted to date and want to thank our investigators and patients for their participation. We believe this is an area in need of a better alternative for patients who are seeking new options to repair cartilage defects that potentially offer both a more rapid recovery and durable response over time with fewer repeat surgeries," stated Gloria Matthews, Chief Medical Officer of Histogenics. "We believe the MRI data, while limited in the number of patients, provide additional confirmatory evidence of previously reported clinical efficacy outcomes, and demonstrate the potential benefits to patients with cartilage defects. We are looking forward to the availability of additional data from the continuing development of this promising treatment alternative," continued Dr. Matthews.The demonstrated rapid maturation of cartilage as evidenced by the MRI data from the Phase 1 and Phase 2 clinical trials is consistent with biomechanical data recently presented by Histogenics and Cornell University that showed that in vitro cartilage constructs, or tissue implants, produced using a process that is designed to mimic that of NeoCart exhibited mechanical properties prior to implantation that were similar to that of native cartilage. These results suggest that the maturation of tissue-engineered cartilage implants, such as NeoCart, leads to improved mechanical properties prior to implantation and may result in a more rapid recovery and return to function for patients suffering from cartilage defects."We believe the data from these two clinical trials are compelling and provide further evidence that NeoCart implants may provide an improved alternative for patients with knee cartilage defects," stated, Dr. Dennis Crawford, Department of Orthopaedics & Rehabilitation, Oregon Health & Science University. "The NeoCart implants appear to improve knee function and quality of life two years after surgery with maintenance through five years," continued Dr. Crawford.